Side Effects With a Focus on Lymphadenopathy Following COVID-19 Vaccination in Pediatric and AYA Oncology Patients.
Jennifer A BelskyWhitney R CarrollGuang XuSeethal A JacobPublished in: Journal of pediatric hematology/oncology (2023)
The Coronavirus Disease 2019 (COVID-19) pandemic led to the swift development of multiple vaccinations. Vaccine side effects were well-documented in the healthy adult cohort and included fever and lymphadenopathy, however, side effects in the pediatric immunocompromised population have not been reported. This retrospective study investigated vaccine-eligible children and adolescent young adult oncology patients 12 to 35 years old. We found uncommon, mild, and self-limiting side effects among pediatric cancer patients and survivors. This data will help guide pediatric and AYA oncologists in providing anticipatory guidance and serve as a guide to managing lymphadenopathy as a potential confounder of malignancy.
Keyphrases
- coronavirus disease
- young adults
- end stage renal disease
- chronic kidney disease
- ejection fraction
- childhood cancer
- palliative care
- prognostic factors
- mental health
- patient reported outcomes
- machine learning
- intensive care unit
- risk assessment
- artificial intelligence
- climate change
- mechanical ventilation
- respiratory failure